Panda Križevci | Krizevci
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups | Circulation
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
Increased Small Low-Density Lipoprotein Particle Number | Circulation
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation
Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use | Circulation
Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places
Cipele Valek
Panda Križevci | Krizevci
Panda Križevci | Krizevci
Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials | Journal of the American Heart Association
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups | Circulation
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome | Circulation
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism | Circulation
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk | Circulation: Cardiovascular Quality and Outcomes
Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups | Circulation
FB2019 Deu BF PDF | PDF
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk | Circulation
Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease | Arteriosclerosis, Thrombosis, and Vascular Biology
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk | Circulation
Panda Križevci | Krizevci
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol | Circulation
Bernd Wullich's research works | Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen (FAU) and other places
